| Bioactivity | STAD 2 is a potent and selective disruptor of PKA-RII, with a Kd of 6.2 nM. STAD 2 disrupts interactions between PKA and AKAP in an isoform-selective manner. STAD 2 displays antimalarial activity through a PKA-independent mechanism[1][2]. |
| Name | STAD 2 |
| CAS | 1542100-77-5 |
| Sequence | {PEG3}-Lys-Lys-Leu-Ala-Lys-Phe-Leu-Val-Ser-{Aaa}-Ala-Leu-Lys-{Aaa}-Ala-Leu-Lys (Covalent bridge:Aaa10-Aaa14) |
| Shortening | {PEG3}-KKLAKFLVS{Aaa}ALK{Aaa}ALK (Covalent bridge:Aaa10-Aaa14) |
| Formula | C102H182N24O22 |
| Molar Mass | 2096.68 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
STAD 2
CAS: 1542100-77-5 F: C102H182N24O22 W: 2096.68
STAD 2 is a potent and selective disruptor of PKA-RII, with a Kd of 6.2 nM. STAD 2 disrupts interactions between PKA and
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.